Brainstorm Cell Therapeutics (BCLI) Stock Price, News & Analysis

Company Overview

BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI) is a clinical‐stage biotechnology company focused on developing autologous cell therapies for the treatment of neurodegenerative diseases. The company’s proprietary platform leverages mesenchymal stem cells (MSCs) that are engineered to secrete neurotrophic and growth factors designed to support neuronal survival and function.

The company’s lead product candidate, NurOwn, is an autologous MSC therapy currently in advanced clinical development for amyotrophic lateral sclerosis (ALS). NurOwn has received orphan drug designations in multiple jurisdictions and is being evaluated in a pivotal clinical program. In addition to ALS, BrainStorm is exploring potential applications of its cell therapy platform in other neurodegenerative disorders such as multiple sclerosis and Parkinson’s disease.

Founded in 2000 and headquartered in Petach Tikva, Israel, BrainStorm maintains research and development operations as well as a current good manufacturing practice (cGMP) cell‐processing facility. The company also operates an office in New York City, facilitating collaborations with U.S. clinical sites and regulatory agencies. This infrastructure supports late‐stage trials and positions BrainStorm for potential commercial supply should regulatory approval be achieved.

BrainStorm collaborates with leading academic institutions and regulatory authorities to advance its clinical pipeline while maintaining robust data transparency. Guided by a management team with expertise in regenerative medicine, neurology and biopharmaceutical development, the company aims to address significant unmet medical needs in the global neurodegenerative disease market.

Key Stats

• Today's Range: $0.68 to $0.71
• 50-Day Range: $0.62 to $0.95
• 52-Week Range: $0.46 to $1.33
• Volume: 1,817 shs
• Average Volume: 16,586 shs
• Market Capitalization: $7.50 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Hold

Brainstorm Cell Therapeutics Stock Analysis - MarketRank™

Brainstorm Cell Therapeutics scored higher than 2% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 1.0 / 5
• Analyst Rating: Hold

Consensus Rating

Brainstorm Cell Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no strong buy ratings, no buy ratings, 1 hold rating, and no sell ratings.

Amount of Analyst Coverage

Brainstorm Cell Therapeutics has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Brainstorm Cell Therapeutics are expected to grow in the coming year, from ($3.01) to ($1.60) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Brainstorm Cell Therapeutics is -0.20, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Brainstorm Cell Therapeutics is -0.20, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: N/A
• Short Interest Level: N/A

Short Interest

There is no current short interest data available for BCLI.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Brainstorm Cell Therapeutics does not currently pay a dividend.

Dividend Growth

Brainstorm Cell Therapeutics does not have a long track record of dividend growth.

News and Social Media

• Score: 0.0 / 5
• News Sentiment: 0.00

News Coverage This Week

MarketBeat has tracked 2 news articles for Brainstorm Cell Therapeutics this week, compared to 0 articles on an average week.

Company Ownership

• Score: 0.6 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Brainstorm Cell Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

11.15% of the stock of Brainstorm Cell Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

14.33% of the stock of Brainstorm Cell Therapeutics is held by institutions.

Company Calendar

• Last Earnings: 5/15/2025
• Today: 5/26/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:BCLI
• CIK: 1137883
• Web: www.brainstorm-cell.com
• Phone: (201) 488-0460
• Fax: N/A
• Employees: 40
• Year Founded: 2004

Profitability

• EPS (Trailing Twelve Months): ($1.64)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$11.62 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: -519.50%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.21
• Quick Ratio: 0.21

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($1.36) per share
• Price / Book: -0.50

Miscellaneous

• Outstanding Shares: 11,035,000
• Free Float: 8,742,000
• Market Cap: $7.50 million
• Optionable: Optionable
• Beta: 0.22